← All trials
NCT05548023
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 16, 2020
- Primary completion
- Apr 4, 2024
- Completion date
- Jul 4, 2024
- First posted
- Sep 21, 2022
- Last posted
- Sep 21, 2022
- Enrollment
- 17
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Chinese University of Hong KongLead sponsor
- Chinese University of Hong KongOverall official - principal investigator
- Chinese University of Hong KongReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.